Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Invested Capital (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Return on Invested Capital data on record, last reported at 0.12% in Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 30.0% year-over-year to 0.12%; the TTM value through Dec 2025 reached 0.12%, up 30.0%, while the annual FY2025 figure was 0.16%, 36.0% up from the prior year.
  • Return on Invested Capital reached 0.12% in Q4 2025 per APLS's latest filing, down from 0.6% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.6% in Q3 2025 and bottomed at 2.51% in Q4 2022.
  • Average Return on Invested Capital over 5 years is 1.07%, with a median of 0.9% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: tumbled -171bps in 2023, then soared 226bps in 2024.
  • A 5-year view of Return on Invested Capital shows it stood at 2.22% in 2021, then dropped by -13bps to 2.51% in 2022, then increased by 3bps to 2.43% in 2023, then soared by 93bps to 0.18% in 2024, then skyrocketed by 166bps to 0.12% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.12% in Q4 2025, 0.6% in Q3 2025, and 0.42% in Q2 2025.